Logical Assessment
Long/short equity, biotech, healthcare, small-cap

6 Reasons Advaxis May Be The Best Reward Vs. Risk In Healthcare

I've looked at dozens of companies, and I believe that Advaxis (NASDAQ:ADXS) has one of the best reward/risk profiles in the healthcare sector. Advaxis is exploring the potential of its bioengineered bacterium, Listeria Monocytogenes, as a robust cancer immunotherapeutic targeting multiple types of cancers. Its attractive reward/risk profile stems from the following trends:

  1. Increasing Prevalence of HPV-Caused Cancers
  • HPV - Human Papillomavirus is the most common STD in the U.S.
  • HPV and Cancer - HPV is associated with multiple types of cancers.

2. ADXS-HPV Targets HPV-Caused Cancers

    Listeria-based Immunotherapy - Novel Bacteria based immunotherapy may hold the key to addressing HPV-caused cancers. ADXS-HPV's Mechanism of Action Implies Significant Benefits - Bioengineered Listeria has the potential to coordinate ...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details